Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.
作者信息
Connolly Caoilfhionn M, Ruddy Jake A, Boyarsky Brian J, Avery Robin K, Werbel William A, Segev Dorry L, Garonzik-Wang Jacqueline, Paik Julie J
机构信息
Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
Surgery, Johns Hopkins, Baltimore, Maryland, USA.
出版信息
Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.
2
Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.
Rheumatology (Oxford). 2022 Oct 6;61(10):e302-e304. doi: 10.1093/rheumatology/keac298.
3
Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado .
Ann Rheum Dis. 2023 Dec;82(12):e228. doi: 10.1136/annrheumdis-2022-222118. Epub 2022 Jul 11.
4
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
5
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.
6
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases.
Ann Rheum Dis. 2022 Mar;81(3):440-441. doi: 10.1136/annrheumdis-2021-221587. Epub 2021 Nov 26.
7
SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists.
Ann Rheum Dis. 2021 Jul;80(7):953-954. doi: 10.1136/annrheumdis-2021-220059. Epub 2021 Feb 23.
8
Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
Front Immunol. 2022 Mar 31;13:846248. doi: 10.3389/fimmu.2022.846248. eCollection 2022.
9
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.
Ann Rheum Dis. 2022 Mar;81(3):422-432. doi: 10.1136/annrheumdis-2021-221575. Epub 2021 Dec 7.
10
Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'.
Ann Rheum Dis. 2021 Oct;80(10):e168. doi: 10.1136/annrheumdis-2021-220586. Epub 2021 May 7.
引用本文的文献
1
Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review.
Rheum Dis Clin North Am. 2025 Feb;51(1):75-92. doi: 10.1016/j.rdc.2024.08.005. Epub 2024 Oct 15.
2
The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI.
Brain Behav. 2024 Jul;14(7):e3587. doi: 10.1002/brb3.3587.
3
What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
Drug Saf. 2024 Oct;47(10):1011-1023. doi: 10.1007/s40264-024-01449-x. Epub 2024 Jun 22.
4
Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines.
BMC Rheumatol. 2024 Jun 17;8(1):25. doi: 10.1186/s41927-024-00396-5.
5
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.
RMD Open. 2023 Nov 29;9(4):e003400. doi: 10.1136/rmdopen-2023-003400.
6
Dermatomyositis Flare-Up Following the SARS-CoV-2 Vaccine: A Case Report and Literature Review.
Cureus. 2023 Aug 29;15(8):e44324. doi: 10.7759/cureus.44324. eCollection 2023 Aug.
7
Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.
Immun Inflamm Dis. 2023 May;11(5):e858. doi: 10.1002/iid3.858.
8
CVAPPS: A Cross-Sectional Study of SARS-CoV-2 Vaccine Acceptance, Perceptions, and Post-Vaccination Side Effects among Rheumatic Disease Patients in Kuwait.
Vaccines (Basel). 2023 Mar 15;11(3):666. doi: 10.3390/vaccines11030666.
9
COVID-19 vaccine uptake, hesitancy and clinical effects on patients with Takayasu's arteritis: A web-based questionnaire survey from a large cohort.
Front Immunol. 2023 Feb 9;14:1030810. doi: 10.3389/fimmu.2023.1030810. eCollection 2023.
10
Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series.
J Clin Med. 2022 Dec 16;11(24):7484. doi: 10.3390/jcm11247484.
本文引用的文献
1
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases.
Lancet Rheumatol. 2021 Apr;3(4):e243-e245. doi: 10.1016/S2665-9913(21)00039-4. Epub 2021 Feb 22.
2
Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
Transplantation. 2021 May 1;105(5):e56-e57. doi: 10.1097/TP.0000000000003654.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases.
Arthritis Res Ther. 2014 Dec 23;16(6):506. doi: 10.1186/s13075-014-0506-0.
Zotero 插件